Please use a minimum of three unique search words
Our search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Taltz ® (ixekizumab)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
Can Taltz® (ixekizumab) be used in Patients with COVID-19 (Coronavirus disease 2019)?
At this time, Lilly has not studied the use of ixekizumab in patients with COVID-19 nor in patients at risk of contracting COVID-19.
Ixekizumab Treatment in Patients with Suspected or Confirmed COVID-19
At this time, Lilly has not studied the use of ixekizumab in patients with coronavirus disease 2019 (COVID-19).
Ixekizumab should not be used during active COVID-19 infection and may be resumed after medical consultation and infection is resolved.1
- If COVID-19 is confirmed, ixekizumab should be immediately discontinued and may be resumed after medical consultation and infection is resolved.1
- If COVID-19 infection is suspected and signs and symptoms of acute infection occur, the patient should consult with their healthcare provider and seek medical advice for guidance on continuing and initiating ixekizumab treatment.1
For current NICE guidance, please refer to 'COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders' www.nice.org.uk/guidance/ng167.
Use of Ixekizumab in High Risk Areas
At this time, Lilly has not studied the use of ixekizumab in patients at risk of contracting COVID-19.
The decision on treatment remains at the discretion of prescribing physician.
COVID-19 is an active respiratory infection, which is typically mild and may also lead to acute respiratory distress syndrome which can be lethal.1
Infectious Disease Resources
For the most current information regarding COVID-19 and Coronavirus, please refer to the websites of local health authorities and/or WHO at WHO Coronavirus disease (COVID-19) outbreak.
Ixekizumab Infection-Related Warnings and Precautions according to the SmPC
Ixekizumab is contraindicated in patients with clinically important active infections (e. g. active tuberculosis).2
Treatment with ixekizumab is associated with an increased rate of infections such as upper respiratory tract infection, oral candidiasis, conjunctivitis, and tinea infections.2
Ixekizumab should be used with caution in patients with clinically important chronic infection or a history of recurrent infection. Patients should be instructed to seek medical advice if signs or symptoms suggestive of an infection occur. If an infection develops, monitor carefully and discontinue ixekizumab if the patient is not responding to standard therapy or the infection becomes serious. Ixekizumab should not be resumed until the infection resolves.2
For further information please refer to the Taltz SmPC.
1Data on file, Eli Lilly and Company and/or one of its subsidiaries.
2Taltz [summary of product characteristics]. Eli Lilly and Company (Ireland) Limited, Ireland
Lilly = Eli Lilly and Company
WHO = World Health Organization
Date of Last Review: 25 February 2020